⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505679 | 0.81 | ALDH1A1 (0.38) | — | |
| SCHEMBL1759861 | 0.78 | — | — | |
| SCHEMBL4473045 | 0.78 | ADH1B (0.39) | — | |
| SCHEMBL12921486 | 0.78 | CA12 (0.36) | — | |
| SCHEMBL14388744 | 0.74 | ADH1B (0.56) | — | |
| SCHEMBL3197403 | 0.74 | — | — | |
| SCHEMBL211319 | 0.74 | — | — | |
| SCHEMBL12391588 | 0.73 | TSHR (0.38) | — | |
| SCHEMBL30080118 | 0.72 | — | — | |
| Methane SCHEMBL28714950 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751069-B1 | METHOD FOR PRODUCING EDDN AND/OR EDMN | BASF SE (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9096497-B2 | Process for preparing EDDN and EDMN | BASF SE (DE) | 2015-08-04 | — | — | US | disclosed |
| US-8952156-B2 | Process for working up reaction outputs from the hydrogenation of EDDN or EDMN | BASF SE (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8946459-B2 | Process for preparing EDDN and/or EDMN by reacting EDFA and/or EDMFA with HCN | BASF SE (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20130090453-A1 | Process for preparing TETA and DETA | BASF SE (DE) | 2013-04-11 | — | — | US | disclosed |
| US-20130085286-A1 | Unknown | BASF SE (DE) | 2013-04-04 | — | — | US | disclosed |
| US-20130079492-A1 | PROCESS FOR PREPARING EDDN AND EDMN | BASF SE (DE) | 2013-03-28 | — | — | US | disclosed |
| WO-2013030258-A1 | METHOD FOR PROCESSING REACTION PRODUCT STEMMING FROM THE HYDROGENATION OF EDDN OR EDMN | BASF SE (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | disclosed |
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |